Search

Your search keyword '"Turco, Fabio"' showing total 287 results
Start Over Author "Turco, Fabio"
287 results on '"Turco, Fabio"'

2. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

Author

Flippot, Ronan, Telli, Tugce, Velev, Maud, Fléchon, Aude, De Vries-Brilland, Manon, Turpin, Léa, Bergman, Andries, Turco, Fabio, Mahammedi, Hakim, Fendler, Wolfgang P., Giraudet, Anne-Laure, Josset, Quentin, Montravers, Françoise, Vogel, Wouter, Gillessen, Silke, Berardi Vilei, Simona, Herrmann, Ken, Kryza, David, Paone, Gaetano, Hadaschik, Boris, Merlin, Charles, Dufour, Pierre-Alban, Bernard-Tessier, Alice, Naoun, Natacha, Patrikidou, Anna, Garcia, Camilo, Foulon, Stéphanie, Pagès, Arnaud, and Fizazi, Karim

Published
2024
Full Text
View/download PDF

3. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives

Author

Turco, Fabio, Buttigliero, Consuelo, Delcuratolo, Marco Donatello, Gillessen, Silke, Vogl, Ursula Maria, Zilli, Thomas, Fossati, Nicola, Gallina, Andrea, Farinea, Giovanni, Di Stefano, Rosario Francesco, Calabrese, Mariangela, Saporita, Isabella, Crespi, Veronica, Poletto, Stefano, Palesandro, Erica, Di Maio, Massimo, Scagliotti, Giorgio Vittorio, and Tucci, Marcello

Published
2024
Full Text
View/download PDF

5. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis

Author

Pisano, Chiara, Turco, Fabio, Arnaudo, Elena, Fea, Elena, Vanella, Paola, Ruatta, Fiorella, Filippi, Roberto, Brusa, Federica, Prati, Veronica, Vana, Federica, Mennitto, Alessia, Cattrini, Carlo, Vignani, Francesca, Dionisio, Rossana, Icardi, Massimiliano, Guglielmini, Pamela, Buosi, Roberta, Stevani, Ilaria, Vormola, Roberto, Numico, Gianmauro, Depetris, Ilaria, Comandone, Alessandro, Gennari, Alessandra, Airoldi, Mario, Rossi, Maura, Vellani, Giorgio, Ortega, Cinzia, Tucci, Marcello, Maio, Massimo Di, and Buttigliero, Consuelo

Published
2024
Full Text
View/download PDF

6. Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health

Author

Turco, Fabio, Brugnatelli, Viola, and Abalo, Raquel

Subjects
Medical research -- Physiological aspects, Medicine, Experimental -- Physiological aspects, Microbiota (Symbiotic organisms) -- Physiological aspects, Gastrointestinal system -- Physiological aspects, Gastrointestinal diseases -- Physiological aspects, Permeability -- Physiological aspects, Health
Abstract

The maintenance of homeostasis in the gastrointestinal (GI) tract is ensured by the presence of the endocannabinoid system (ECS), which regulates important physiological activities, such as motility, permeability, fluid secretion, immunity, and visceral pain sensation. Beside its direct effects on the GI system, the ECS in the central nervous system indirectly regulates GI functions, such as food intake and energy balance. Mounting evidence suggests that the ECS may play an important role in modulating central neurotransmission which affects GI functioning. It has also been found that the interaction between the ECS and microbiota affects brain and gut activity in a bidirectional manner, and a number of studies demonstrate that there is a strong relationship between GI dysfunctions and mood disorders. Thus, microbiota can regulate the tone of the ECS. Conversely, changes in intestinal ECS tone may influence microbiota composition. In this mini-review, we propose the concept of neuro-gastro-cannabinology as a novel and alternative paradigm for studying and treating GI disorders that affect mood, as well as mood disorders that imbalance GI physiology. This concept suggests the use of prebiotics or probiotics for improving the tone of the ECS, as well as the use of phytocannabinoids or endocannabinoid-like molecules, such as palmitoylethanolamide, to restore the normal intestinal microbiota. This approach may be effective in ameliorating the negative effects of GI dysfunctions on mood and/or the effects of mood disorders on digestive health. Keywords: Cannabinoid treatment, Gut-brain axis, Mood disorders, Gastroinstestinal disorders, Probiotics, Endocannabinoid system, Author(s): Fabio Turco [a]; Viola Brugnatelli [a]; Raquel Abalo [b,c,d] Introduction Homeostasis is derived from the ancient Greek words á½[mu]Î¿Î¹Î¿Ï and ÏÏάÏιÏ, meaning 'staying the same'. As a biological concept, [...]

Published
2023
Full Text
View/download PDF

7. Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study

Author

Rossi, Alessandro, Aimar, Giacomo, Audisio, Marco, Bungaro, Maristella, Caglio, Andrea, Di Liello, Raimondo, Gamba, Teresa, Gargiulo, Piera, Ghisoni, Eleonora, Lombardi, Pasquale, Marandino, Laura, Mariniello, Annapaola, Paratore, Chiara, Reale, Maria Lucia, Trastu, Federica, Tuninetti, Valentina, Turco, Fabio, Fabi, Alessandra, Perrone, Francesco, and Di Maio, Massimo

Published
2023
Full Text
View/download PDF

8. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

9. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

11. Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis.

Author

Turco, Fabio, primary, Saporita, Isabella, additional, Calabrese, Mariangela, additional, Carfi, Federica Maria, additional, Mogavero, Andrea, additional, Treglia, Giorgio, additional, Gillessen, Silke, additional, Di Maio, Massimo, additional, Tucci, Marcello, additional, ButtIgliero, Consuelo, additional, and Vogl, Ursula, additional

Published
2024
Full Text
View/download PDF

12. EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors

Author

Grisay, Guillaume, primary, Turco, Fabio, additional, Litiere, Saskia, additional, Fournier, Béatrice, additional, Patrikidou, Anna, additional, Gallardo, Enrique, additional, McDermott, Ray, additional, Alanya, Ahu, additional, Gillessen, Silke, additional, and Tombal, Bertrand, additional

Published
2024
Full Text
View/download PDF

14. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis.

Author

Farinea, Giovanni, Calabrese, Mariangela, Carfì, Federica, Saporita, Isabella, Poletto, Stefano, Delcuratolo, Marco Donatello, Turco, Fabio, Audisio, Marco, Di Stefano, Francesco Rosario, Tucci, Marcello, and Buttigliero, Consuelo

Subjects
CASTRATION-resistant prostate cancer, ANDROGEN receptors, IMMUNOSTAINING, PROSTATE biopsy, NEUROENDOCRINE tumors
Abstract

Neuroendocrine differentiation (NED) represents a possible androgen receptor pathway inhibitors (ARPI) resistance mechanism in metastatic castration resistance prostate cancer (mCRPC). As mCRPC with NED has been excluded from clinical trials evaluating ARPI efficacy, this study investigates the prognostic impact of NED in mCRPC patients treated with ARPIs. Methods: We retrospectively analyzed 327 mCRPC patient data treated with Enzalutamide or Abiraterone in the first and second or successive lines of treatment. NED was assessed using prostate biopsy samples through immunohistochemical staining. Results: NED was confirmed in 32/327 (9.8%) mCRPC patients. In the overall population, mCRPC with NED showed worse PFS (4.38 vs. 11.48 months HR 2.505 [1.71–3.68] p < 0.05), disease control rate (DCR), and PSA response. In the first line setting, mCRPC with NED demonstrated worse PFS (8.5 vs. 14.9 months HR 2.13 [1.18–3.88], p < 0.05). Similarly, in the second or successive lines, mCRPC with NED showed worse PFS (4.0 vs. 7.5 months HR 2.43 [1.45–4.05] p < 0.05), DCR, PSA response and OS (12.53 vs. 18.03 months HR 1.86 [1.12–3.10] p < 0.05). The adverse impact of NED on PFS was consistence across all subgroups; we also noted a trend of worse PFS in patients with high vs. low NED. Conclusions: In our study, mCRPC with NED treated with Enzalutamide or Abiraterone showed worse clinical outcomes. NED assessment should be considered to optimize treatment decisions in the mCRPC setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. X-BASE: the first terrestrial carbon and water flux products from an extended data-driven scaling framework, FLUXCOM-X

Author

Nelson, Jacob A., primary, Walther, Sophia, additional, Gans, Fabian, additional, Kraft, Basil, additional, Weber, Ulrich, additional, Novick, Kimberly, additional, Buchmann, Nina, additional, Migliavacca, Mirco, additional, Wohlfahrt, Georg, additional, Šigut, Ladislav, additional, Ibrom, Andreas, additional, Papale, Dario, additional, Göckede, Mathias, additional, Duveiller, Gregory, additional, Knohl, Alexander, additional, Hörtnagl, Lukas, additional, Scott, Russell L., additional, Zhang, Weijie, additional, Hamdi, Zayd Mahmoud, additional, Reichstein, Markus, additional, Aranda-Barranco, Sergio, additional, Ardö, Jonas, additional, Op de Beeck, Maarten, additional, Billdesbach, Dave, additional, Bowling, David, additional, Bracho, Rosvel, additional, Brümmer, Christian, additional, Camps-Valls, Gustau, additional, Chen, Shiping, additional, Cleverly, Jamie Rose, additional, Desai, Ankur, additional, Dong, Gang, additional, El-Madany, Tarek S., additional, Euskirchen, Eugenie Susanne, additional, Feigenwinter, Iris, additional, Galvagno, Marta, additional, Gerosa, Giacomo, additional, Gielen, Bert, additional, Goded, Ignacio, additional, Goslee, Sarah, additional, Gough, Christopher Michael, additional, Heinesch, Bernard, additional, Ichii, Kazuhito, additional, Jackowicz-Korczynski, Marcin Antoni, additional, Klosterhalfen, Anne, additional, Knox, Sara, additional, Kobayashi, Hideki, additional, Kohonen, Kukka-Maaria, additional, Korkiakoski, Mika, additional, Mammarella, Ivan, additional, Mana, Gharun, additional, Marzuoli, Riccardo, additional, Matamala, Roser, additional, Metzger, Stefan, additional, Montagnani, Leonardo, additional, Nicolini, Giacomo, additional, O'Halloran, Thomas, additional, Ourcival, Jean-Marc, additional, Peichl, Matthias, additional, Pendall, Elise, additional, Ruiz Reverter, Borja, additional, Roland, Marilyn, additional, Sabbatini, Simone, additional, Sachs, Torsten, additional, Schmidt, Marius, additional, Schwalm, Christopher R., additional, Shekhar, Ankit, additional, Silberstein, Richard, additional, Silveira, Maria Lucia, additional, Spano, Donatella, additional, Tagesson, Torbern, additional, Tramontana, Gianluca, additional, Trotta, Carlo, additional, Turco, Fabio, additional, Vesala, Timo, additional, Vincke, Caroline, additional, Vitale, Domenico, additional, Vivoni, Enrique R., additional, Wang, Yi, additional, Woodgate, William, additional, Yepez, Enrico A., additional, Zhang, Junhui, additional, Zona, Donatella, additional, and Jung, Martin, additional

Published
2024
Full Text
View/download PDF

19. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma

Author

Samuelly, Alessandro, primary, Di Stefano, Rosario Francesco, additional, Turco, Fabio, additional, Delcuratolo, Marco Donatello, additional, Pisano, Chiara, additional, Saporita, Isabella, additional, Calabrese, Mariangela, additional, Carfì, Federica Maria, additional, Tucci, Marcello, additional, and Buttigliero, Consuelo, additional

Published
2024
Full Text
View/download PDF

20. Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer

Author

Calabrese, Mariangela, primary, Saporita, Isabella, additional, Turco, Fabio, additional, Gillessen, Silke, additional, Castro, Elena, additional, Vogl, Ursula Maria, additional, Di Stefano, Rosario Francesco, additional, Carfì, Federica Maria, additional, Poletto, Stefano, additional, Farinea, Giovanni, additional, Tucci, Marcello, additional, and Buttigliero, Consuelo, additional

Published
2023
Full Text
View/download PDF

22. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis

Author

Pisano, Chiara, primary, Turco, Fabio, additional, Arnaudo, Elena, additional, Fea, Elena, additional, Vanella, Paola, additional, Ruatta, Fiorella, additional, Filippi, Roberto, additional, Brusa, Federica, additional, Prati, Veronica, additional, Vana, Federica, additional, Mennitto, Alessia, additional, Cattrini, Carlo, additional, Vignani, Francesca, additional, Dionisio, Rossana, additional, Icardi, Massimiliano, additional, Guglielmini, Pamela, additional, Buosi, Roberta, additional, Stevani, Ilaria, additional, Vormola, Roberto, additional, Numico, Gianmauro, additional, Depetris, Ilaria, additional, Comandone, Alessandro, additional, Gennari, Alessandra, additional, Airoldi, Mario, additional, Rossi, Maura, additional, Vellani, Giorgio, additional, Ortega, Cinzia, additional, Tucci, Marcello, additional, Maio, Massimo Di, additional, and Buttigliero, Consuelo, additional

Published
2023
Full Text
View/download PDF

23. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)

Author

Gillessen, Silke, primary, Procopio, Giuseppe, additional, Hayoz, Stefanie, additional, Kremer, Eloïse, additional, Schwitter, Michael, additional, Caffo, Orazio, additional, Lorente, David, additional, Pedrazzini, Augusto, additional, Roubaud, Guilhem, additional, Nenan, Soazig, additional, Omlin, Aurelius, additional, Buttigliero, Consuelo, additional, Delgado Mingorance, Juan Ignacio, additional, González-del-Alba, Aránzazu, additional, Delgado, Maria Teresa, additional, Nole, Franco, additional, Turco, Fabio, additional, Pereira Mestre, Ricardo, additional, Ribi, Karin, additional, and Cathomas, Richard, additional

Published
2023
Full Text
View/download PDF

25. Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer.

Author

Calabrese, Mariangela, Saporita, Isabella, Turco, Fabio, Gillessen, Silke, Castro, Elena, Vogl, Ursula Maria, Di Stefano, Rosario Francesco, Carfì, Federica Maria, Poletto, Stefano, Farinea, Giovanni, Tucci, Marcello, and Buttigliero, Consuelo

Subjects
ANDROGEN receptors, CASTRATION-resistant prostate cancer, PROSTATE cancer, METASTASIS
Abstract

Androgen receptor pathway inhibitors (ARPI) and polyadenosine diphosphate-ribose inhibitors (PARPi) are part of the standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC). There is biological evidence that the association of ARPI and PARPi could have a synergistic effect; therefore, several ongoing clinical trials are investigating the efficacy of this combination with preliminary results that are not perfectly concordant in identifying patients who can obtain the most benefit from this therapeutic option. The purpose of this review is to describe the PARPi mechanisms of action and to analyze the biological mechanisms behind the interplay between the androgen receptor and the PARPi system to better understand the rationale of the ARPI + PARPi combinations. Furthermore, we will summarize the preliminary results of the ongoing studies on these combinations, trying to understand in which patients to apply. Finally, we will discuss the clinical implications of this combination and its possible future perspectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study

Author

Marandino, Laura, primary, Trastu, Federica, additional, Ghisoni, Eleonora, additional, Lombardi, Pasquale, additional, Mariniello, Annapaola, additional, Reale, Maria Lucia, additional, Aimar, Giacomo, additional, Audisio, Marco, additional, Bungaro, Maristella, additional, Caglio, Andrea, additional, Di Liello, Raimondo, additional, Gamba, Teresa, additional, Gargiulo, Piera, additional, Paratore, Chiara, additional, Rossi, Alessandro, additional, Tuninetti, Valentina, additional, Turco, Fabio, additional, Perrone, Francesco, additional, and Di Maio, Massimo, additional

Published
2023
Full Text
View/download PDF

27. Germline testing for men with prostate cancer: Need to broaden the indications in Europe?

Author

Trevisi, Elena, primary, Koster, Kira-Lee, additional, Heinimann, Karl, additional, Zuerrer, Ursina, additional, Turco, Fabio, additional, Bosetti, Davide Giovanni, additional, Colombo, Ilaria, additional, Maitz, Silvia, additional, Nerone, Marta, additional, Omlin, Aurelius Gabriel, additional, Vogl, Ursula, additional, Gillessen, Silke, additional, and Graffeo, Rossella, additional

Published
2023
Full Text
View/download PDF

28. Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.

Author

Flippot, Ronan, primary, Telli, Tugce, additional, Velev, Maud, additional, Flechon, Aude, additional, Turpin, Lea, additional, Bergman, Andre M., additional, Turco, Fabio, additional, Fendler, Wolfgang Peter, additional, Giraudet, Anne Laure, additional, Montravers, Françoise, additional, Vogel, Wouter V., additional, Gillessen, Silke, additional, Berardi, Simona, additional, Herrmann, Ken, additional, Kryza, David, additional, Paone, Gaetano, additional, Garcia, Camilo, additional, Foulon, Stéphanie, additional, Pages, Arnaud, additional, and Fizazi, Karim, additional

Published
2023
Full Text
View/download PDF

29. Management of Patients with Advanced Prostate Cancer. Part I:Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, Omlin, Aurelius, Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Abstract

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical man

Published
2023

30. Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience

Author

Persano, Irene, primary, Cani, Massimiliano, additional, Del Rio, Benedetta, additional, Ferrari, Giorgia, additional, Garbo, Edoardo, additional, Parlagreco, Elena, additional, Pisano, Chiara, additional, Cetoretta, Valeria, additional, Delcuratolo, Marco Donatello, additional, Turco, Fabio, additional, Audisio, Alessandro, additional, Cecchi, Cristina, additional, Leone, Gianmarco, additional, Napoli, Valerio Maria, additional, Bertaglia, Valentina, additional, Bianco, Valentina, additional, Capelletto, Enrica, additional, D’Amiano, Carmen, additional, Di Maio, Massimo, additional, Gianetta, Martina, additional, Novello, Silvia, additional, Passiglia, Francesco, additional, Scagliotti, Giorgio Vittorio, additional, and Bironzo, Paolo, additional

Published
2023
Full Text
View/download PDF

31. Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study

Author

ANGUSTI, Tiziana, primary, DI STEFANO, Rosario F., additional, PARENTE, Antonella, additional, BUNGARO, Maristella, additional, TURCO, Fabio, additional, SAMUELLY, Alessandro, additional, PISANO, Chiara, additional, SCAGLIOTTI, Giorgio V., additional, DI MAIO, Massimo, additional, TUCCI, Marcello, additional, and BUTTIGLIERO, Consuelo, additional

Published
2023
Full Text
View/download PDF

32. How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?

Author

Turco, Fabio, primary, Di Prima, Lavinia, additional, Pisano, Chiara, additional, Poletto, Stefano, additional, De Filippis, Marco, additional, Crespi, Veronica, additional, Farinea, Giovanni, additional, Cani, Massimiliano, additional, Calabrese, Mariangela, additional, Saporita, Isabella, additional, Di Stefano, Rosario Francesco, additional, Tucci, Marcello, additional, and Buttigliero, Consuelo, additional

Published
2023
Full Text
View/download PDF

34. Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs

Author

Turco,Fabio, Gillessen,Silke, Cathomas,Richard, Buttigliero,Consuelo, and Vogl,Ursula Maria

Subjects
Research and Reports in Urology
Abstract

Fabio Turco,1,2 Silke Gillessen,1,3 Richard Cathomas,4 Consuelo Buttigliero,2 Ursula Maria Vogl1 1IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; 2Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, 10043, Italy; 3Universita della Svizzera Italiana, Lugano, Switzerland; 4Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, SwitzerlandCorrespondence: Fabio Turco, IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland, Tel +39 3927704290, Fax +41 0918119061, Email turcofabio9@gmail.comAbstract: Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease. However, in recent years, several treatments have been shown to improve the outcome of CRPC patients both in the non-metastatic (nmCRPC) as well as the metastatic setting (mCRPC). In nmCRPC patients with a PSA doubling time < 10 months, the addition of enzalutamide, apalutamide and darolutamide to androgen deprivation therapy (ADT) compared to ADT alone resulted in improved metastases free (MFS) and overall survival (OS). For mCRPC patients, several treatment options have been shown to be effective: two taxane based chemotherapies (docetaxel and cabazitaxel), two androgen-receptor pathway inhibitors (ARPI) (abiraterone and enzalutamide), two radiopharmaceutical agents (radium 223 and 177Lutetium-PSMA-617), one immunotherapy treatment (sipuleucel-T) and two poly ADP-ribose polymerase (PARP) inhibitors (olaparib and rucaparib). Pembrolizumab is US Food and Drug Administration (FDA) approved in all MSI high solid tumors, although a very small proportion of prostate cancer patients harboring this characteristic will benefit. Despite having a broad variety of treatments available, there are still several unmet clinical needs for CRPC. The objective of this review was to describe the therapeutic landscape in CRPC patients, to identify criteria for selecting patients for specific treatments currently available, and to address the current challenges in this setting.Keywords: prostate cancer, castration resistant prostate cancer, non-metastatic castration resistant prostate cancer, metastatic castration resistant prostate cancer

Published
2022

36. Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy

Author

Turco, Fabio, primary, Tucci, Marcello, additional, Delcuratolo, Marco Donatello, additional, Di Stefano, Rosario Francesco, additional, Pisano, Chiara, additional, Audisio, Alessandro, additional, Audisio, Marco, additional, Ungaro, Antonio, additional, Ortega, Cinzia, additional, Di Maio, Massimo, additional, Scagliotti, Giorgio Vittorio, additional, and Buttigliero, Consuelo, additional

Published
2022
Full Text
View/download PDF

37. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Turco, Fabio, primary, Armstrong, Andrew, additional, Attard, Gerhardt, additional, Beer, Tomasz M., additional, Beltran, Himisha, additional, Bjartell, Anders, additional, Bossi, Alberto, additional, Briganti, Alberto, additional, Bristow, Rob G., additional, Bulbul, Muhammad, additional, Caffo, Orazio, additional, Chi, Kim N., additional, Clarke, Caroline, additional, Clarke, Noel, additional, Davis, Ian D., additional, de Bono, Johann, additional, Duran, Ignacio, additional, Eeles, Ros, additional, Efstathiou, Eleni, additional, Efstathiou, Jason, additional, Evans, Christopher P., additional, Fanti, Stefano, additional, Feng, Felix Y., additional, Fizazi, Karim, additional, Frydenberg, Mark, additional, George, Dan, additional, Gleave, Martin, additional, Halabi, Susan, additional, Heinrich, Daniel, additional, Higano, Celestia, additional, Hofman, Michael S., additional, Hussain, Maha, additional, James, Nicholas, additional, Jones, Rob, additional, Kanesvaran, Ravindran, additional, Khauli, Raja B., additional, Klotz, Laurence, additional, Leibowitz, Raya, additional, Logothetis, Christopher, additional, Maluf, Fernando, additional, Millman, Robin, additional, Morgans, Alicia K., additional, Morris, Michael J., additional, Mottet, Nicolas, additional, Mrabti, Hind, additional, Murphy, Declan G., additional, Murthy, Vedang, additional, Oh, William K., additional, Ekeke Onyeanunam, Ngozi, additional, Ost, Piet, additional, O'Sullivan, Joe M., additional, Padhani, Anwar R., additional, Parker, Christopher, additional, Poon, Darren M.C., additional, Pritchard, Colin C., additional, Rabah, Danny M., additional, Rathkopf, Dana, additional, Reiter, Robert E., additional, Rubin, Mark, additional, Ryan, Charles J., additional, Saad, Fred, additional, Pablo Sade, Juan, additional, Sartor, Oliver, additional, Scher, Howard I., additional, Shore, Neal, additional, Skoneczna, Iwona, additional, Small, Eric, additional, Smith, Matthew, additional, Soule, Howard, additional, Spratt, Daniel, additional, Sternberg, Cora N., additional, Suzuki, Hiroyoshi, additional, Sweeney, Christopher, additional, Sydes, Matthew, additional, Taplin, Mary-Ellen, additional, Tilki, Derya, additional, Tombal, Bertrand, additional, Türkeri, Levent, additional, Uemura, Hiroji, additional, Uemura, Hirotsugu, additional, van Oort, Inge, additional, Yamoah, Kosj, additional, Ye, Dingwei, additional, Zapatero, Almudena, additional, Gillessen, Silke, additional, and Omlin, Aurelius, additional

Published
2022
Full Text
View/download PDF

38. Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?

Author

Audisio, Marco, primary, Buttigliero, Consuelo, additional, Turco, Fabio, additional, Delcuratolo, Marco Donatello, additional, Pisano, Chiara, additional, Parlagreco, Elena, additional, Di Stefano, Rosario Francesco, additional, Di Prima, Lavinia, additional, Crespi, Veronica, additional, Farinea, Giovanni, additional, Cani, Massimiliano, additional, and Tucci, Marcello, additional

Published
2022
Full Text
View/download PDF

39. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Turco, Fabio, Armstrong, Andrew, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N, Clarke, Caroline S, Clarke, Noel, Davis, Ian D, de Bono, Johann, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celestia, Hofman, Michael S, Hussain, Maha, James, Nicholas, Jones, Rob, Kanesvaran, Ravindran, Khauli, Raja B, Klotz, Laurence, Leibowitz, Raya, Logothetis, Christopher, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ekeke, Onyeanunam N, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Christopher, Poon, Darren M C, Pritchard, Colin C, Rabah, Danny M, Rathkopf, Dana, Reiter, Robert E, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Gillessen, Silke, Omlin, Aurelius, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Turco, Fabio, Armstrong, Andrew, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N, Clarke, Caroline S, Clarke, Noel, Davis, Ian D, de Bono, Johann, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celestia, Hofman, Michael S, Hussain, Maha, James, Nicholas, Jones, Rob, Kanesvaran, Ravindran, Khauli, Raja B, Klotz, Laurence, Leibowitz, Raya, Logothetis, Christopher, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ekeke, Onyeanunam N, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Christopher, Poon, Darren M C, Pritchard, Colin C, Rabah, Danny M, Rathkopf, Dana, Reiter, Robert E, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Gillessen, Silke, and Omlin, Aurelius

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

Published
2022

40. Corrigendum to 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021' [Eur Urol 2022].

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Turco, Fabio, Armstrong, Andrew, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N, Clarke, Caroline, Clarke, Noel, Davis, Ian D, de Bono, Johann, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celestia, Hofman, Michael S, Hussain, Maha, James, Nicholas, Jones, Rob, Kanesvaran, Ravindran, Khauli, Raja B, Klotz, Laurence, Leibowitz, Raya, Logothetis, Christopher, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ekeke, Onyeanunam Ngozi, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Christopher, Poon, Darren M C, Pritchard, Colin C, Rabah, Danny M, Rathkopf, Dana, Reiter, Robert E, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Gillessen, Silke, Omlin, Aurelius, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Turco, Fabio, Armstrong, Andrew, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N, Clarke, Caroline, Clarke, Noel, Davis, Ian D, de Bono, Johann, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celestia, Hofman, Michael S, Hussain, Maha, James, Nicholas, Jones, Rob, Kanesvaran, Ravindran, Khauli, Raja B, Klotz, Laurence, Leibowitz, Raya, Logothetis, Christopher, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ekeke, Onyeanunam Ngozi, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Christopher, Poon, Darren M C, Pritchard, Colin C, Rabah, Danny M, Rathkopf, Dana, Reiter, Robert E, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Gillessen, Silke, and Omlin, Aurelius

Published
2022

41. Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Tilki, Derya, Gillessen, Silke; Bossi, Alberto; Davis, Ian D.; de Bono, Johann; Fizazi, Karim; James, Nicholas D.; Mottet, Nicolas; Shore, Neal; Small, Eric; Smith, Mathew; Sweeney, Christopher; Tombal, Bertrand; Antonarakis, Emmanuel S.; Aparicio, Ana M.; Armstrong, Andrew J.; Attard, Gerhardt; Beer, Tomasz M.; Beltran, Himisha; Bjartell, Anders; Blanchard, Pierre; Briganti, Alberto; Bristow, Rob G.; Bulbul, Muhammad; Caffo, Orazio; Castellano, Daniel; Castro, Elena; Cheng, Heather H.; Chi, Kim N.; Chowdhury, Simon; Clarke, Caroline S.; Clarke, Noel; Daugaard, Gedske; De Santis, Maria; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Ngozi Ekeke, Onyeanunam; Evans, Christopher P.; Fanti, Stefano; Feng, Felix Y.; Fonteyne, Valerie; Fossati, Nicola; Frydenberg, Mark; George, Daniel; Gleave, Martin; Gravis, Gwenaelle; Halabi, Susan; Heinrich, Daniel; Herrmann, Ken; Higano, Celestia; Hofman, Michael S.; Horvath, Lisa G.; Hussain, Maha; Jereczek-Fossa, Barbara Alicja; Jones, Robert; Kanesvaran, Ravindran; Kellokumpu-Lehtinen, Pirkko-Liisa; Khauli, Raja B.; Klotz, Laurence; Kramer, Gero; Leibowitz, Raya; Logothetis, Christopher J.; Mahal, Brandon A.; Maluf, Fernando; Mateo, Joaquin; Matheson, David; Mehra, Niven; Merseburger, Axel; Morgans, Alicia K.; Morris, Michael J.; Mrabti, Hind; Mukherji, Deborah; Murphy, Declan G.; Murthy, Vedang; Nguyen, Paul L.; Oh, William K.; Ost, Piet; O'Sullivan, Joe; Padhani, Anwar R.; Pezaro, Carmel; Poon, Darren M.C.; Pritchard, Colin C.; Rabah, Danny M.; Rathkopf, Dana; Reiter, Robert E.; Rubin, Mark. A.; Ryan, Charles J.; Saad, Fred; Pablo Sade, Juan; Sartor, Oliver A.; Scher, Howard I.; Sharifi, Nima; Skoneczna, Iwona; Soule, Howard; Spratt, Daniel E.; Srinivas, Sandy; Sternberg, Cora N.; Steuber, Thomas; Suzuki, Hiroyoshi; Sydes, Matthew R.; Taplin, Mary-Ellen; Türkeri, Levent; Turco, Fabio; Uemura, Hiroji; Uemura, Hirotsugu; Ürün, Yüksel; Vale, Claire L.; van Oort, Inge; Vapiwala, Neha; Walz, Jochen; Yamoah, Kosj; Ye, Dingwei; Yu, School of Medicine, Tilki, Derya, Gillessen, Silke; Bossi, Alberto; Davis, Ian D.; de Bono, Johann; Fizazi, Karim; James, Nicholas D.; Mottet, Nicolas; Shore, Neal; Small, Eric; Smith, Mathew; Sweeney, Christopher; Tombal, Bertrand; Antonarakis, Emmanuel S.; Aparicio, Ana M.; Armstrong, Andrew J.; Attard, Gerhardt; Beer, Tomasz M.; Beltran, Himisha; Bjartell, Anders; Blanchard, Pierre; Briganti, Alberto; Bristow, Rob G.; Bulbul, Muhammad; Caffo, Orazio; Castellano, Daniel; Castro, Elena; Cheng, Heather H.; Chi, Kim N.; Chowdhury, Simon; Clarke, Caroline S.; Clarke, Noel; Daugaard, Gedske; De Santis, Maria; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Ngozi Ekeke, Onyeanunam; Evans, Christopher P.; Fanti, Stefano; Feng, Felix Y.; Fonteyne, Valerie; Fossati, Nicola; Frydenberg, Mark; George, Daniel; Gleave, Martin; Gravis, Gwenaelle; Halabi, Susan; Heinrich, Daniel; Herrmann, Ken; Higano, Celestia; Hofman, Michael S.; Horvath, Lisa G.; Hussain, Maha; Jereczek-Fossa, Barbara Alicja; Jones, Robert; Kanesvaran, Ravindran; Kellokumpu-Lehtinen, Pirkko-Liisa; Khauli, Raja B.; Klotz, Laurence; Kramer, Gero; Leibowitz, Raya; Logothetis, Christopher J.; Mahal, Brandon A.; Maluf, Fernando; Mateo, Joaquin; Matheson, David; Mehra, Niven; Merseburger, Axel; Morgans, Alicia K.; Morris, Michael J.; Mrabti, Hind; Mukherji, Deborah; Murphy, Declan G.; Murthy, Vedang; Nguyen, Paul L.; Oh, William K.; Ost, Piet; O'Sullivan, Joe; Padhani, Anwar R.; Pezaro, Carmel; Poon, Darren M.C.; Pritchard, Colin C.; Rabah, Danny M.; Rathkopf, Dana; Reiter, Robert E.; Rubin, Mark. A.; Ryan, Charles J.; Saad, Fred; Pablo Sade, Juan; Sartor, Oliver A.; Scher, Howard I.; Sharifi, Nima; Skoneczna, Iwona; Soule, Howard; Spratt, Daniel E.; Srinivas, Sandy; Sternberg, Cora N.; Steuber, Thomas; Suzuki, Hiroyoshi; Sydes, Matthew R.; Taplin, Mary-Ellen; Türkeri, Levent; Turco, Fabio; Uemura, Hiroji; Uemura, Hirotsugu; Ürün, Yüksel; Vale, Claire L.; van Oort, Inge; Vapiwala, Neha; Walz, Jochen; Yamoah, Kosj; Ye, Dingwei; Yu, and School of Medicine

Abstract

Background: innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: to present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: consensus was defined as ?75% agreement, with strong consensus defined as ?90% agreement. Results and limitations: the voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: these voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage, We gratefully acknowledge the following organisations for providing financial support for the APCCC 2022: The City of Lugano and Movember Foundation. Ros Eeles is supported by a National Institute of Health Research grant to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. We also acknowledge sponsorship from several for-profit organisations for APCCC 2022, including Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer Health Care, Debio-pharm, MSD, Janssen Oncology, Myovant Sciences, Orion Pharma, Pfizer Oncology, Roche, Telix Innovations SA, Ferring Pharmaceuticals, Lantheus, and Tolmar. These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication.

Published
2022

42. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 2022]

Author

Turco, Fabio, primary, Armstrong, Andrew, additional, Attard, Gerhardt, additional, Beer, Tomasz M., additional, Beltran, Himisha, additional, Bjartell, Anders, additional, Bossi, Alberto, additional, Briganti, Alberto, additional, Bristow, Rob G., additional, Bulbul, Muhammad, additional, Caffo, Orazio, additional, Chi, Kim N., additional, Clarke, Caroline, additional, Clarke, Noel, additional, Davis, Ian D., additional, de Bono, Johann, additional, Duran, Ignacio, additional, Eeles, Ros, additional, Efstathiou, Eleni, additional, Efstathiou, Jason, additional, Evans, Christopher P., additional, Fanti, Stefano, additional, Feng, Felix Y., additional, Fizazi, Karim, additional, Frydenberg, Mark, additional, George, Dan, additional, Gleave, Martin, additional, Halabi, Susan, additional, Heinrich, Daniel, additional, Higano, Celestia, additional, Hofman, Michael S., additional, Hussain, Maha, additional, James, Nicholas, additional, Jones, Rob, additional, Kanesvaran, Ravindran, additional, Khauli, Raja B., additional, Klotz, Laurence, additional, Leibowitz, Raya, additional, Logothetis, Christopher, additional, Maluf, Fernando, additional, Millman, Robin, additional, Morgans, Alicia K., additional, Morris, Michael J., additional, Mottet, Nicolas, additional, Mrabti, Hind, additional, Murphy, Declan G., additional, Murthy, Vedang, additional, Oh, William K., additional, Ekeke, Onyeanunam Ngozi, additional, Ost, Piet, additional, O'Sullivan, Joe M., additional, Padhani, Anwar R., additional, Parker, Christopher, additional, Poon, Darren M.C., additional, Pritchard, Colin C., additional, Rabah, Danny M., additional, Rathkopf, Dana, additional, Reiter, Robert E., additional, Rubin, Mark, additional, Ryan, Charles J., additional, Saad, Fred, additional, Sade, Juan Pablo, additional, Sartor, Oliver, additional, Scher, Howard I., additional, Shore, Neal, additional, Skoneczna, Iwona, additional, Small, Eric, additional, Smith, Matthew, additional, Soule, Howard, additional, Spratt, Daniel, additional, Sternberg, Cora N., additional, Suzuki, Hiroyoshi, additional, Sweeney, Christopher, additional, Sydes, Matthew, additional, Taplin, Mary-Ellen, additional, Tilki, Derya, additional, Tombal, Bertrand, additional, Türkeri, Levent, additional, Uemura, Hiroji, additional, Uemura, Hirotsugu, additional, van Oort, Inge, additional, Yamoah, Kosj, additional, Ye, Dingwei, additional, Zapatero, Almudena, additional, Gillessen, Silke, additional, and Omlin, Aurelius, additional

Published
2022
Full Text
View/download PDF

43. Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis

Author

Turco, Fabio, primary, Tucci, Marcello, additional, Angusti, Tiziana, additional, Parente, Antonella, additional, Di Stefano, Rosario Francesco, additional, Urban, Susanna, additional, Pisano, Chiara, additional, Samuelly, Alessandro, additional, Audisio, Alessandro, additional, Audisio, Marco, additional, Parlagreco, Elena, additional, Ungaro, Antonio, additional, Scagliotti, Giorgio Vittorio, additional, Di Maio, Massimo, additional, and Buttigliero, Consuelo, additional

Published
2022
Full Text
View/download PDF

44. Prostate Cancer and Sleep Disorders: A Systematic Review

Author

Sparasci, Davide, primary, Napoli, Ilenia, additional, Rossi, Lorenzo, additional, Pereira-Mestre, Ricardo, additional, Manconi, Mauro, additional, Treglia, Giorgio, additional, Marandino, Laura, additional, Ottaviano, Margaret, additional, Turco, Fabio, additional, Mangan, Dylan, additional, Gillessen, Silke, additional, and Vogl, Ursula Maria, additional

Published
2022
Full Text
View/download PDF

47. sj-pdf-18-tmj-10.1177_03008916221077144 – Supplemental material for Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis

Author

Turco, Fabio, Tucci, Marcello, Angusti, Tiziana, Parente, Antonella, Di Stefano, Rosario Francesco, Urban, Susanna, Pisano, Chiara, Samuelly, Alessandro, Audisio, Alessandro, Audisio, Marco, Parlagreco, Elena, Ungaro, Antonio, Scagliotti, Giorgio Vittorio, Di Maio, Massimo, and Buttigliero, Consuelo

Subjects
Medicine
Abstract

Supplemental material, sj-pdf-18-tmj-10.1177_03008916221077144 for Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis by Fabio Turco, Marcello Tucci, Tiziana Angusti, Antonella Parente, Rosario Francesco Di Stefano, Susanna Urban, Chiara Pisano, Alessandro Samuelly, Alessandro Audisio, Marco Audisio, Elena Parlagreco, Antonio Ungaro, Giorgio Vittorio Scagliotti, Massimo Di Maio and Consuelo Buttigliero in Tumori Journal

Published
2022
Full Text
View/download PDF

48. Darolutamide in Metastatic Prostate Cancer

Author

Turco, Fabio, Tucci, Marcello, and Buttigliero, Consuelo

Subjects
Male, Hormones, Humans, Pyrazoles, Androgen Receptor Antagonists, Prostatic Neoplasms
Published
2022

49. sj-pdf-23-tmj-10.1177_03008916221077144 – Supplemental material for Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis

Author

Turco, Fabio, Tucci, Marcello, Angusti, Tiziana, Parente, Antonella, Di Stefano, Rosario Francesco, Urban, Susanna, Pisano, Chiara, Samuelly, Alessandro, Audisio, Alessandro, Audisio, Marco, Parlagreco, Elena, Ungaro, Antonio, Scagliotti, Giorgio Vittorio, Di Maio, Massimo, and Buttigliero, Consuelo

Subjects
Medicine
Abstract

Supplemental material, sj-pdf-23-tmj-10.1177_03008916221077144 for Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis by Fabio Turco, Marcello Tucci, Tiziana Angusti, Antonella Parente, Rosario Francesco Di Stefano, Susanna Urban, Chiara Pisano, Alessandro Samuelly, Alessandro Audisio, Marco Audisio, Elena Parlagreco, Antonio Ungaro, Giorgio Vittorio Scagliotti, Massimo Di Maio and Consuelo Buttigliero in Tumori Journal

Published
2022
Full Text
View/download PDF

50. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (vol 82, pg 6, 2022)

Author

Turco, Fabio, Armstrong, Andrew, Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline, Clarke, Noel, Davis, Ian D., de Bono, Johann, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celestia, Hofman, Michael S., Hussain, Maha, James, Nicholas, Jones, Rob, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Christopher, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ekeke, Onyeanunam Ngozi, Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Christopher, Poon, Darren M. C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel, Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Turkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Gillessen, Silke, Omlin, Aurelius, and Acibadem University Dspace

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results